Clinical Efficacy of Rituximab Combined with Lenalidomide in Maintenance Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma
Objective To analyze the clinical efficacy of rituximab combined with lenalidomide in maintenance treatment of elderly patients with diffuse large B cell lymphoma(DLBCL).Methods A total of 62 elderly patients with DLBCL in complete remission after R-CHOP chemotherapy in Xuchang Traditional Chinese Medicine Hospital from February 2019 to February 2021 were selected as the research objects by random sampling method.The randomized grouping method was adopted divided into combined treatment group(31 cases)and monotherapy group(31 cases).The monotherapy group was treated with rituximab after complete remission,and the combined treatment group was treated with rituximab combined with lenalidomide after complete remission.Neutrophil/lymphocyte ratio(NLR),platelet/lymphocyte ratio(PLR),immunoglobulin G(IgG),immunoglobulin A(IgA),interleukin-10(IL-10)and interferon-y(INF-γ)were compared between the two groups.The incidence of adverse reactions was compared between the two groups.Results After treatment,NLR and PLR in the combined treatment group were lower than those in the monotherapy group(P＜0.05).After treatment,the levels of IgG and IgA in the combined treatment group were higher than those in the monotherapy group(P＜0.05).After treatment,the levels of IL-10 and INF-γin the combined treatment group were lower than those in the monotherapy group(P＜0.05).There was no significant difference in the incidence of adverse reactions between the combined treatment group and the monotherapy group(P＞0.05).Conclusion Rituximab combined with lenalidomide maintenance therapy for elderly patients with DLBCL can regulate the expression of cytokines,and improve tumor inflammatory state and host anti-tumor immune state.
diffuse large B cell lymphomathe agedmaintenance treatmentrituximablenalidomide
万方数据
维普
